ABO - Óskare Capital: Partnership Announcement
Retrieved on:
Wednesday, January 26, 2022
Professional Services, Alternative Medicine, Health, Finance, Pharmaceutical, Biotechnology, ECS, OTC, Therapy, Health Insurance Innovations, TSX, CPH, RIV, NEO, Partnership, ESG, EIS, Cannabinoid, CN, VC, ABO, Record, Agtech, CIO, Capital, Health, Venture capital, CSE, SEIS, MMQ, European, Nasdaq, ASX, Innovation, DE, Fine chemical, Risk management, Óskare Capital SAS, Alpha Blue Ocean, ÓSKARE CAPITAL SAS, ALPHA BLUE OCEAN
Alpha Blue Ocean (ABO) and skare Capital are announcing today the formation of a strategic partnership to collaborate on investment opportunities associated with cannabis plant-based medicines as well as synthetic molecules that target the mammalian Endocannabinoid system (ECS).
Key Points:
- Alpha Blue Ocean (ABO) and skare Capital are announcing today the formation of a strategic partnership to collaborate on investment opportunities associated with cannabis plant-based medicines as well as synthetic molecules that target the mammalian Endocannabinoid system (ECS).
- Furthermore, because of favorable valuations there are readily available opportunities for ABO and skare to invest in and scale.
- skare Capitals Chairman, Bruce Linton notes: skare Capital is delighted to be joining forces with ABO.
- skare surrounded themselves with a stellar team whose experience spans all sectors of this new multibillion dollar industry.